1 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 7 Phase 1, 5 Phase 2.
Follow azeliragon: new trials by email Literature Review of azeliragon trials Research Report on azeliragon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer Azeliragon, T-DXd - T-dxd Resistant HER2-Positive, HER2 Low Metastatic Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 27 | 2026-12-01 | 2026-08-25 |
| Concurrent Azeliragon With Craniospinal Irradiation Azeliragon, CSI - Solid Tumor, High-grade Glioma | Phase 1 | Active not recruiting | NYU Langone Health | 21 | 2025-02-18 | 2026-05-18 |
| Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma Azeliragon, Biospecimen Collection, Computed Tomography - Glioblastoma, Malignant Glioma | Phase 1 | Withdrawn | City of Hope Medical Center | 2024-11-15 | 2024-09-19 | |
| Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Azeliragon, Stereotactic radiosurgery, Corticosteroid - Cancer, Metastasis | Phase 1 / Phase 2 | Suspended | Baptist Health South Florida | 46 | 2023-11-17 | 2026-06-16 |
| Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg - Glioblastoma | Phase 1 / Phase 2 | Completed | Cantex Pharmaceuticals | 33 | 2023-09-05 | 2026-10-19 |
| RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer TTP488, ddAC/ddT, TC - Cancer Related Cognitive Decline, Non-metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Georgetown University | 48 | 2023-06-06 | 2025-12-24 |
| Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer Azeliragon - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Cantex Pharmaceuticals | 30 | 2023-06-01 | 2024-06-14 |
Glioblastoma (2) · Glioma (2) · Brain Neoplasms (1) · Meningeal Carcinomatosis (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Cantex Pharmaceuticals (2) · Baptist Health South Florida (1) · City of Hope Medical Center (1) · Georgetown University (1) · NYU Langone Health (1) · The Methodist Hospital Research Institute (1)
United States (4) · Spain (1)
Andrew Hendifar, MD (1) · Candace Mainor, MD (1) · Jana L Portnow (1) · Jonathan Yang, MD, PhD (1) · Minesh Mehta, M.D. (1)
P30CA033572 (1), U19CA264512 (1)